Vol.

No.

April 13, 2018Apr 13, 2018

DOWNLOAD THE PDF

Cover Story

Sharpless: Expect a big boost to NCI's RPG pool

By Matthew Bin Han Ong

NCI's Research Project Grant pool is likely to receive the largest increase in funding in 16 years, NCI Director Norman “Ned” Sharpless said at an NCI Town Hall meeting April 10.

Whistleblower suit claims McKesson repackaged, sold cancer drug “overfill”

By Paul Goldberg

Clinical Free Trials & Tribulations

Sales Revenues at the Potential Expense of Patient Safety:
The Example of You&i

By Mark J. Ratain, Lisa S. Chen, Allen S. Lichter, R. Donald Harvey, Sonali M. Smith, Leonard B. Saltz, William G. Wierda, Varsha V. Gandhi and Michael J. Keating

In Brief

Gradishar named chief of hematology and Oncology at Northwestern

Cole named chief of pediatric hematology/oncology at Rutgers

ACS CAN report examines patient barriers to cancer clinical trial enrollment

Woodcock, Shaw and Conway-Welch receive awards from Society for Women's Health Research

Billings appointed chief medical officer at Natera

Funding Opportunities

DOD Ovarian Cancer Research Program Publishes funding opportunities

Clinical Roundup

NCI study revises molecular classification for most common type of lymphoma

Updated ASTRO guideline for lung radiation recommends concurrent chemotherapy for some stage III patients

Keytruda monotherapy meets OS endpoint in phase III trial

Epacadostat plus Keytruda don't meet PFS endpoint in phase III study in metastatic melanoma

Roswell Park, Ohio State researchers identify genes linked to blood and marrow transplant outcomes

Drugs & Targets

Rucaparib approved for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer

FDA finalizes guidances to accelerate development of Next Gen sequencing

Karyopharm's Selinexor receive FDA Fast Track designation

MD Anderson, Nanobiotix to collaborate on preclinical research combining NBTXR3, nivolumab

PREVIOUS ISSUE

NEXT ISSUE